We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Rapid POC Tuberculosis Test Provides Results Within 15 Minutes

By LabMedica International staff writers
Posted on 09 Dec 2025

Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. More...

Current diagnostic tools often require advanced laboratory infrastructure, trained personnel, and long processing times, making them difficult to implement in rural or low-resource regions. In a new study, researchers evaluated a rapid test that delivers same-day results without specialized equipment, aiming to expand access to preventive treatment.

Researchers at Karolinska Institutet (Solna, Stockholm, Sweden), working with collaborators in Vietnam, assessed TB-Feron, a point-of-care test that detects latent tuberculosis infection within 15 minutes. They compared it to the standard laboratory test, QuantiFERON-TB Gold Plus, which requires multiple processing steps and one to two days for results. The study included 345 adults divided into three groups based on confirmed TB status, household exposure, or no known exposure. All participants were tested using both methods for direct comparison.

The findings, published in Clinical Infectious Diseases, showed that TB-Feron had a high sensitivity of 88%, identifying most individuals expected to test positive. QuantiFERON-TB Gold Plus showed a slightly higher sensitivity of 92%. Specificity for TB-Feron reached 70%, compared with 96% for the standard test, indicating a moderate ability to rule out infection in healthy individuals. Among household contacts, the two tests showed strong agreement, with 92% concordance in positive samples.

Researchers also assessed reproducibility to ensure the test’s reliability in real-world settings. Their findings from two laboratory groups showed no systematic differences, supporting consistent test performance across operators. The team noted that TB-Feron’s rapid, user-friendly format made it particularly practical for primary care and community-based screening where laboratory services are limited. They anticipate that this approach could improve early detection and broaden access to preventive therapy.

“This test can help more people with latent tuberculosis to be detected and receive preventive treatment, especially in rural areas in countries with limited resources,” said Lina Davies Forsman, last author of the study.

Related Links:
Karolinska Institutet


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: ARIA can appear as brain swelling or small hemorrhages on MRI scans and remains difficult to predict before treatment begins (Reisa A, Sperling et al, via Wikimedia Commons, CC BY 4.0)

Blood Immune 'Fingerprint' Predicts Side Effects of New Alzheimer's Drug

New antibody therapies for Alzheimer’s disease have shown promise in slowing disease progression, but their broader use has been limited by a common side effect known as amyloid-related imaging abnormalities (ARIA).... Read more

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.